The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $530,791 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Florida (UF) to investigate the metabolic mechanisms that distinguish the selection of foreign-antigen specific B cells versus autoreactive B cells. The project aims to define the ITCH-regulated metabolic pathways in B cells that govern the selection of protective foreign-antigen specific responses...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $367,332 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Florida State University to pilot a Youth Learning Health Community in North Florida. The project aims to define implementation strategies, conduct simulations, and perform a proof-of-concept study to optimize the implementation of HIV prevention interventions tailored for youth. The University of Florida is a sub-awardee, contributing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $304,280 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Broad Institute, Inc. to conduct deep integration of multi-omics and patient health data to clarify risk factors of enterococcal infective endocarditis. The key objectives are to: 1) curate and assess patient health and demographic variables to detect characteristics associated with infective endocarditis; 2) perform...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,225,986 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Chicago. The grant, titled "Computational Models of Adaptive Immunity to Influenza," aims to investigate factors that determine strong, durable, and broadly protective adaptive immune responses to influenza vaccination, particularly in individuals with prior influenza virus exposure....
The University of Washington was awarded a $477,226 federal Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, which runs from August 2024 to July 2029, aims to understand how microbial eukaryotes, such as amoeba, defend against giant viruses in the Megavirales family. The research will combine principles of virus-host interactions, AI-driven protein structure prediction, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to determine the molecular, cellular, and evolutionary mechanisms by which certain viruses evade or co-opt innate immune peptides called defensins to enhance their infectivity. The $148,568 award, spanning from November 2024 to June 2026, will be conducted at the University of Washington. The research aims...
This $728,244 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to investigate the mechanisms of virulence factors and injectisome assembly in bacterial pathogens like Salmonella, Shigella, Vibrio, Pseudomonas, Yersinia, and Chlamydia. The research aims to provide fundamental knowledge about injectisome function and gene regulatory systems, which is crucial for...
This $190,058 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to define the role of the ADAM9 protein in the immune response to SARS-CoV-2 infection and its impact on COVID-19-induced lung injury. The research, to be conducted at the University of Massachusetts Medical School from December 2024 through November 2029, aims to further understand the ADAM9/MDA5...
This $682,008 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to advance the development of monoclonal antibody (mAb) therapeutics for the treatment of paramyxovirus infections, with a specific focus on parainfluenza virus (PIV). The key objectives are to: 1) define the human B cell repertoire to the PIV fusion (F) and hemagglutinin-neuraminidase (HN) surface proteins, 2)...
The University of Washington was awarded a $350,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, with a period of performance from August 9, 2024 to June 30, 2025, will fund research to define the interactions and transcription programs activated by components of the "necroptotic" cell death pathway, and to evaluate the roles of necroptotic transcription and cell...
The University of Florida was awarded a $632,585 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, with a period of performance from July 18, 2024 to May 31, 2026, will fund research to elucidate the differences in innate and adaptive immune mechanisms during viral myocarditis between pediatric and adult populations, with a focus on the role of sex, age, and hormone status. This work aims to advance scientific understanding of the complex immunological factors underlying viral myocarditis, a potentially serious heart condition, with the goal of improving diagnostic and treatment approaches for both pediatric and adult patients.